Maria Grazia Roncarolo

Last updated

Maria Grazia Roncarolo
Born1954 (age 70–71)
Turin, Italy
Alma mater University of Turin
Scientific career
Institutions Stanford University

Maria Grazia Roncarolo (born 17 December 1954) is an Italian pediatrician who is currently George D. Smith Professor in Stem Cell and Regenerative Medicine and Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) at Stanford University. [1] She is also the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine along with Irving Weissman and Michael Longaker and the Director for Center for Definitive and Curative Medicine at Stanford. [2]

Contents

She was educated at the University of Turin. [1] She is a past President of the Federation of Clinical Immunology Societies, [3] and is a member of the Austrian Academy of Sciences. [4] She is an academic founder of Graphite Bio. [5] She has an h-index of 91. [6]

Awards and honors

Research career

Roncarolo is well known for identifying a peripheral subset of regulatory T cells, called type 1 regulatory T (Tr1) cells. Her team was the first to describe Tr1 cells [12] while at DNAX Research Institute of Molecular and Cellular Biology, which was later acquired by Schering-Plough and now a part of Merck. She was the principal investigator of the first clinical trial using Tr1 cells that are generated ex vivo to treat graft-versus-host disease in leukemia patients receiving a haploidentical haematopoietic stem cell transplant [13] and is the principal investigator of an additional clinical trial utilizing these cells in the United States. [14]

Roncarolo has made major contributions in the field of cell and gene therapy.  She performed fetal stem cell transplants given before birth [15] to treat inherited diseases of the immune system such as Wiskott-Aldrich Syndrome [16] She led the first stem cell-based gene therapy trial for patients with adenosine deaminase-severe combined immunodeficiency. [17] The clinical trial results led to the European Commission approval. [18] The therapy was licensed to GlaxoSmithKline and is marketed under the name Strimvelis, making it the first commercially approved ex vivo gene therapy in Europe. [19]

References

  1. 1 2 "Maria Grazia Roncarolo". Stanford University . Retrieved 23 June 2021.
  2. ↑ "Stanford announces new Center for Definitive and Curative Medicine". News Center (in Samoan). Retrieved 8 February 2022.
  3. ↑ "Leadership". Federation of Clinical Immunology Societies . 4 June 2018. Retrieved 26 June 2021.
  4. ↑ "Maria Grazia Roncarolo". Human Technopole. Retrieved 26 June 2021.
  5. ↑ "About Us: Academic Founders". Graphite Bio. Retrieved 26 June 2021.
  6. ↑ "Maria Grazia Roncarolo - Top Italian Scientist in Biomedical Sciences". Top Italian Scientists. Retrieved 26 June 2021.
  7. ↑ "Academy of Europe: ListMembersByAlphabet". www.ae-info.org. Retrieved 8 February 2022.
  8. ↑ "Academy of Europe: Roncarolo Maria". www.ae-info.org. Retrieved 8 February 2022.
  9. ↑ "Awards". www.esgct.eu. Retrieved 29 September 2023.
  10. ↑ "EURORDIS - The Voice of Rare Disease Patients in Europe". www.eurordis.org. Archived from the original on 18 June 2021. Retrieved 8 February 2022.
  11. ↑ "Outstanding Achievement Award | ASGCT - American Society of Gene & Cell Therapy | ASGCT - American Society of Gene & Cell Therapy". asgct.org. Retrieved 8 February 2022.
  12. ↑ Groux, Hervé; O'Garra, Anne; Bigler, Mike; Rouleau, Matthieu; Antonenko, Svetlana; de Vries, Jan E.; Roncarolo, Maria Grazia (October 1997). "A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis". Nature. 389 (6652): 737–742. Bibcode:1997Natur.389..737G. doi:10.1038/39614. PMID   9338786. S2CID   4422991.
  13. ↑ Bacchetta, Rosa; Lucarelli, Barbarella; Sartirana, Claudia; Gregori, Silvia; Lupo Stanghellini, Maria T.; Miqueu, Patrick; Tomiuk, Stefan; Hernandez-Fuentes, Maria; Gianolini, Monica E.; Greco, Raffaella; Bernardi, Massimo (2014). "Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells". Frontiers in Immunology. 5: 16. doi: 10.3389/fimmu.2014.00016 . ISSN   1664-3224. PMC   3907718 . PMID   24550909.
  14. ↑ Roncarolo, Maria Grazia (25 June 2021). "Use of T-allo10 Cell Infusions Combined With Mismatched Related or Mismatched Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies". Stanford University.{{cite journal}}: Cite journal requires |journal= (help)
  15. ↑ "Ailing fetuses to be treated with stem cells". www.science.org. Retrieved 8 February 2022.
  16. ↑ Aiuti, Alessandro; Biasco, Luca; Scaramuzza, Samantha; Ferrua, Francesca; Cicalese, Maria Pia; Baricordi, Cristina; Dionisio, Francesca; Calabria, Andrea; Giannelli, Stefania; Castiello, Maria Carmina; Bosticardo, Marita (23 August 2013). "Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome". Science. 341 (6148). doi:10.1126/science.1233151. PMC   4375961 . PMID   23845947.
  17. ↑ Aiuti, Alessandro; Cattaneo, Federica; Galimberti, Stefania; Benninghoff, Ulrike; Cassani, Barbara; Callegaro, Luciano; Scaramuzza, Samantha; Andolfi, Grazia; Mirolo, Massimiliano; Brigida, Immacolata; Tabucchi, Antonella (29 January 2009). "Gene therapy for immunodeficiency due to adenosine deaminase deficiency". The New England Journal of Medicine. 360 (5): 447–458. doi: 10.1056/NEJMoa0805817 . ISSN   1533-4406. PMID   19179314.
  18. ↑ Aiuti, Alessandro; Roncarolo, Maria Grazia; Naldini, Luigi (June 2017). "Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products". EMBO Molecular Medicine. 9 (6): 737–740. doi:10.15252/emmm.201707573. ISSN   1757-4676. PMC   5452047 . PMID   28396566.
  19. ↑ "Gene Therapy's First Out-and-Out Cure Is Here". MIT Technology Review. Retrieved 8 February 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.